Addendum to ACERH Research Report No.7 Original statement: Entecavir is subsidised only as a second line therapy for patients who have failed

First Page		Document Content
Date: 2010-07-22 00:16:23 Bristol-Myers Squibb Entecavir Lamivudine Adefovir Hepatitis B Pharmaceutical Benefits Scheme Medicine Purines Chemistry Organic chemistry		Addendum to ACERH Research Report No.7 Original statement: Entecavir is subsidised only as a second line therapy for patients who have failed Add to Reading List Source URL: pandora.nla.gov.au Download Document from Source Website File Size: 268,68 KB Share Document on Facebook